Endovasc Reports Nicotine Continues to Demonstrate Extraordinary Angiogenesis.Business Editors/Health & Medical Writers MONTGOMERY, Texas--(BW HealthWire)--Feb. 1, 2001 Endovasc Ltd. Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :ENDV) today announced results of its further animal studies of nicotine receptor agonist (NRA) in rabbit hind-limb ischemia model for critical limb ischemia. The paper, "Nicotine Increases Peripheral Conductance After Femoral Artery Occlusion," was presented by Christopher Heeschen, M.D. at the American Heart Association American Heart Association (AHA), n.pr a national voluntary health agency that has the goal of increasing public and medical awareness of cardiovascular diseases and stroke, and thereby reducing the number of associated deaths and disabilities. (AHA) Scientific Conference on Therapeutic Angiogenesis and Myocardial Laser Revascularization myocardial laser revascularization Heart surgery A procedure in which a laser is used to drill channels in the left ventricle for improved perfusion and oxygenation of heart muscle, treating angina pectoris and myocardial ischemia. Cf Batista procedure. in Santa Fe, N.M. Dr. Heeschen showed results of rabbit studies conducted in Associate Professor John Cooke's Vascular Biology Laboratory at Stanford University School of Medicine Stanford University School of Medicine is affiliated with Stanford University and is located at Stanford University Medical Center in Stanford, California, adjacent to Palo Alto and Menlo Park. . The primary efficacy end point, increased capillary density, angiographically demonstrable collaterization and improved perfusion to the ischemic Ischemic An inadequate supply of blood to a part of the body, caused by partial or total blockage of an artery. Mentioned in: Antiangiogenic Therapy, Subarachnoid Hemorrhage, Ventricular Fibrillation ischemic limb, which was documented by a superior calf blood ratio and improved blood flow in the ischemic at maximal vasodilation vasodilation /vaso·di·la·tion/ (-di-la´shun) 1. increase in caliber of blood vessels. 2. a state of increased caliber of blood vessels. . Dr. Thomas Quertermous, the William G. Irwin Professor of Cardiovascular Medicine and Molecular Cardiology at Stanford University who was also presenting at the conference additional data on stem cell and progenitor endothelial cell recruitment to the ischemic zones by nicotine, remarked, "We have never seen anything like this!" Stem cells and progenitor endothelial cells are utilized by the body to form angioblasts that cause vascular sprouting. Endovasc said its nicotine receptor agonist trial in the hind-limb ischemia rabbit model was the acid test for proof of concept that nicotine produces remarkable angiogenesis in critical ischemic limb. The Company previously observed extraordinary angiogenic response in the mouse model that encouraged higher species experimentation. "These results are better than anything yet seen," said Dr. David P. Summers, Company chairman and CEO. "Compared to Vascular Endothelial Growth Factor Vascular endothelial growth factor (VEGF) is an important signaling protein involved in both vasculogenesis (the de novo formation of the embryonic circulatory system) and angiogenesis (the growth of blood vessels from pre-existing vasculature). (VEGF) in the same model, the results were significantly better" (see J. Clin. Invest. Vol. 93 (Feb. 1994, 662-670)). NRA produced greater capillary density, 4.1 times control group vs. VEGF 2.5 times control group. Calf blood pressure ratio for nicotine was 97 vs. control 68 at day 28 (P=0.008) compared to VEGF (75 vs. control 48 P=less than 0.05) at day 40. "Angiographic evidence, although subjective to interpretation, demonstrated robust collateral development 3 major conducting collaterals 1-2 mm. diameter," said Dr. Summers. The study confirmed data previously presented at both the American College of Cardiology The American College of Cardiology (ACC) is a nonprofit medical association established in 1949 to educate, research and influence health care public policy. The president for the 2006–2007 year is Steven E. Nissen. [1] The organization has 39 chapters in the U.S. and European Society of Cardiology The European Society of Cardiology (ESC) represents more than 50,000 cardiology professionals across Europe and the Mediterranean. Its mission is to reduce the impact of cardiovascular disease in Europe. in March and August last year, respectively. Earlier mouse studies of the nicotine receptor agonist demonstrated significant efficacy over both fibroblast growth factor (FGF) and Del 1. Therapeutic angiogenesis is the growth of new blood vessels and is potentially a non-surgical "biological bypass" for patients with cardiovascular disease (CAD). CAD usually blocks or narrows blood vessels essential for limb circulation and heart function. More than 65 million Americans suffer from some form of CAD (source AHA). Endovasc Ltd. Inc. is a biopharmaceutical/biotech company pioneering liposomal and stent drug delivery technology. The Company's products and processes are covered by patents and trade secrets for competing in a multi-billion dollar market. The company owns the worldwide exclusive license for the newly discovered angiogenesis agent, nicotine receptor agonist. The foregoing statements are made under the "Safe Harbor" Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995 and may contain forward-looking statements that involve risks and uncertainties that may not be evident at the time of this release. For more information about Endovasc Ltd. Inc., contact: |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion